AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3303823 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatinum + 5-Fluoro-uracil
Number of subjects: 0
Study 29767802 — intervention group
Group type: EXPERIMENTAL
Intervention: START-Play intervention (individualized twice-weekly home intervention for 12 weeks)
Number of subjects: 140
Study 29767802 — intervention group
Group type: EXPERIMENTAL
Intervention: START-Play intervention
Number of subjects: 140
Study 29767802 — intervention group
Group type: COMPARATOR
Intervention: Usual care in early intervention (EI)
Number of subjects: 140
Study 27026380 — intervention group
Group type: EXPERIMENTAL
Intervention: Spaced learning using emails to teach psychiatric concepts
Number of subjects: 132
Study 27026380 — intervention group
Group type: COMPARATOR
Intervention: Control group (no emails)
Number of subjects: 132
Study 24549105 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone or aripiprazole (antipsychotic treatment) for 12 weeks
Number of subjects: 35
Study 24549105 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 35
Study 23259270 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture analgesia
Number of subjects: 200
Study 23259270 — intervention group
Group type: COMPARATOR
Intervention: Intravenous anesthesia
Number of subjects: 200
Study 20841532 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-hour course on contextualization
Number of subjects: 124
Study 20841532 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 124
Study 18507721 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity-based lifestyle intervention
Number of subjects: 21
Study 18507721 — intervention group
Group type: COMPARATOR
Intervention: Obese group (before intervention)
Number of subjects: 21
Study 15931516 — intervention group
Group type: EXPERIMENTAL
Intervention: DLB, PD, PDD
Number of subjects: 75
Study 15931516 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 75
Study 12830025 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy-based diet intervention (5 counseling visits, 7 follow-up phone calls, and 12 group meetings)
Number of subjects: 220
Study 12830025 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy-based diet intervention
Number of subjects: 220
Study 12830025 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 220
Study 11028837 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tropisetron (5 mg once daily) for 15 days
Number of subjects: 20
Study 11028837 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ondansetron (2 x 8 mg daily) for 15 days
Number of subjects: 20
Study 8861177 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine 37.5 mg twice daily
Number of subjects: 314
Study 8861177 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine 20 mg once daily
Number of subjects: 314
Study 8861177 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine (increased to 75 mg twice daily after 2 weeks if inadequate response)
Number of subjects: 314
Study 8861177 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine 150 mg daily
Number of subjects: 314
Study 1903808 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 1800
Study 1903808 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1800
Study 6348585 — intervention group
Group type: EXPERIMENTAL
Intervention: Pergolide (mean daily dose 3.3 mg, range 0.7 to 7.2 mg)
Number of subjects: 24
Study 6348585 — intervention group
Group type: COMPARATOR
Intervention: Bromocriptine (mean daily dose 42.7 mg, range 5.8 to 87.5 mg)
Number of subjects: 24
Study 30256229 — intervention group
Group type: EXPERIMENTAL
Intervention: Empowerment program (10 sessions)
Number of subjects: 89
Study 30256229 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 89
Study 30144034 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral Greater Occipital Nerve Block (GONB) with 6 mL of 0.5% bupivacaine
Number of subjects: 28
Study 30144034 — intervention group
Group type: COMPARATOR
Intervention: Sham injection with 1 mL of 0.5% bupivacaine
Number of subjects: 28
Study 27367987 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol 0.015 mg/kg
Number of subjects: 315
Study 27367987 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol 0.03 mg/kg
Number of subjects: 315
Study 27367987 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 315
Study 24927291 — intervention group
Group type: EXPERIMENTAL
Intervention: Fertility-related informational intervention
Number of subjects: 69
Study 24927291 — intervention group
Group type: COMPARATOR
Intervention: Control (alcohol-related informational intervention)
Number of subjects: 69
Study 21480777 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediately loaded implants (40 patients, minimal insertion torque 30 Ncm) with nonoccluding temporary restorations.
Number of subjects: 80
Study 21480777 — intervention group
Group type: COMPARATOR
Intervention: Early loaded implants (40 patients) with definitive restoration after 2 months.
Number of subjects: 80
Study 18435429 — intervention group
Group type: EXPERIMENTAL
Intervention: Early external cephalic version
Number of subjects: 0
Study 18435429 — intervention group
Group type: EXPERIMENTAL
Intervention: Late external cephalic version
Number of subjects: 0
Study 17194733 — intervention group
Group type: EXPERIMENTAL
Intervention: Static magnetic field exposure (0.06-T magnets)
Number of subjects: 15
Study 17194733 — intervention group
Group type: COMPARATOR
Intervention: Placebo exposure (identical mattress without magnets)
Number of subjects: 15
Study 17194733 — intervention group
Group type: EXPERIMENTAL
Intervention: Static magnetic field exposure
Number of subjects: 15
Study 17194733 — intervention group
Group type: COMPARATOR
Intervention: Placebo exposure
Number of subjects: 15
Study 14962235 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose chemotherapy
Number of subjects: 424
Study 14962235 — intervention group
Group type: EXPERIMENTAL
Intervention: Melphalan and prednisone
Number of subjects: 424
Study 14962235 — intervention group
Group type: COMPARATOR
Intervention: Reference population
Number of subjects: 424
Study 12150267 — intervention group
Group type: COMPARATOR
Intervention: Traditional therapies appropriate for the patient
Number of subjects: 45
Study 12150267 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapies appropriate for the patient with an oral vertical exercise device
Number of subjects: 45
Study 12150267 — intervention group
Group type: EXPERIMENTAL
Intervention: Home care education and use of the oral exercise device
Number of subjects: 45
Study 9797793 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg lovastatin after 120 mg diltiazem twice a day for 2 weeks
Number of subjects: 10
Study 9797793 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg pravastatin after 120 mg diltiazem twice a day for 2 weeks
Number of subjects: 10
Study 9797793 — intervention group
Group type: COMPARATOR
Intervention: 20 mg lovastatin
Number of subjects: 10
Study 9797793 — intervention group
Group type: COMPARATOR
Intervention: 20 mg pravastatin
Number of subjects: 10
Study 8109598 — intervention group
Group type: EXPERIMENTAL
Intervention: r-HuEPO 300 U/kg on Days 1, 4, 7, and 10
Number of subjects: 24
Study 8109598 — intervention group
Group type: EXPERIMENTAL
Intervention: r-HuEPO 400 U/kg on Days 1, 5, and 9
Number of subjects: 24
Study 8109598 — intervention group
Group type: EXPERIMENTAL
Intervention: r-HuEPO 600 U/kg on Days 1 and 10
Number of subjects: 24
Study 8109598 — intervention group
Group type: EXPERIMENTAL
Intervention: r-HuEPO administration
Number of subjects: 24
Study 2781119 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous streptokinase (SK)
Number of subjects: 214
Study 2781119 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 214
Study 327364 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone
Number of subjects: 128
Study 327364 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 128
Study 327364 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 128
Study 31021823 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based exercise programming system
Number of subjects: 305
Study 31021823 — intervention group
Group type: COMPARATOR
Intervention: Control (home exercise prescribed by therapist's usual methods)
Number of subjects: 305
Study 28882919 — intervention group
Group type: EXPERIMENTAL
Intervention: THC:CBD oromucosal spray (Sativex)
Number of subjects: 50
Study 28882919 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 25899519 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based palliative approach (HPA)
Number of subjects: 75
Study 25899519 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 75
Study 23578552 — intervention group
Group type: EXPERIMENTAL
Intervention: Glatiramer acetate (GA), daily administration, dosage not specified, duration of therapy not specified.
Number of subjects: 0
Study 21320196 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyurethane foam in contact with the heel inside plaster cast
Number of subjects: 156
Study 21320196 — intervention group
Group type: COMPARATOR
Intervention: Control group without polyurethane foam
Number of subjects: 156
Study 18165591 — intervention group
Group type: EXPERIMENTAL
Intervention: IP meperidine 50 mg
Number of subjects: 250
Study 18165591 — intervention group
Group type: EXPERIMENTAL
Intervention: IP meperidine 100 mg
Number of subjects: 250
Study 18165591 — intervention group
Group type: EXPERIMENTAL
Intervention: IP ropivacaine 150 mg
Number of subjects: 250
Study 18165591 — intervention group
Group type: EXPERIMENTAL
Intervention: IP meperidine 50 mg and ropivacaine 150 mg
Number of subjects: 250
Study 18165591 — intervention group
Group type: COMPARATOR
Intervention: Control (IP saline with IM meperidine 50 mg)
Number of subjects: 250
Study 16517311 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior approach injection of bupivacaine, methylprednisolone, and gadolinium-DTPA
Number of subjects: 33
Study 16517311 — intervention group
Group type: EXPERIMENTAL
Intervention: Anteromedial approach injection of bupivacaine, methylprednisolone, and gadolinium-DTPA
Number of subjects: 33
Study 14626567 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 20 mg + Fenofibrate 200 mg (n = 46)
Number of subjects: 86
Study 14626567 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg + Ciprofibrate 100 mg (n = 40)
Number of subjects: 86
Study 10962119 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular hypertrophy (LVH)
Number of subjects: 111
Study 10962119 — intervention group
Group type: COMPARATOR
Intervention: Normal left ventricular mass
Number of subjects: 111
Study 10962119 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentric LV hypertrophy
Number of subjects: 111
Study 10962119 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric LV hypertrophy
Number of subjects: 111
Study 10962119 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal geometry and mass
Number of subjects: 111
Study 10181621 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous quality improvement for adult clinical preventive services
Number of subjects: 0
Study 10181621 — intervention group
Group type: EXPERIMENTAL
Intervention: Leadership involvement and skill building for change management
Number of subjects: 0
Study 8417220 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine-prilocaine cream (group 1)
Number of subjects: 199
Study 2874366 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal sprays of dexamethasone, tramazoline, and neomycin
Number of subjects: 50
Study 2874366 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal sprays of dexamethasone and tramazoline with no antibiotic
Number of subjects: 50
Study 2874366 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo (propellant alone)
Number of subjects: 50
Study 30056548 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute resistance exercise (RE)
Number of subjects: 35
Study 30056548 — intervention group
Group type: COMPARATOR
Intervention: Non-exercise control condition
Number of subjects: 35
Study 26790360 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy (IPT)
Number of subjects: 88
Study 26790360 — intervention group
Group type: COMPARATOR
Intervention: Health education (HE)
Number of subjects: 88
Study 24801842 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (18 mg, 27 IU) and Vitamin E acetate (27 mg, 27 IU) delivered via tube-feeding
Number of subjects: 6
Study 24801842 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (18 mg, 27 IU) and Vitamin E acetate (27 mg, 27 IU)
Number of subjects: 6
Study 24801842 — intervention group
Group type: EXPERIMENTAL
Intervention: Cubic phase formulation
Number of subjects: 6
Study 22281100 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention Bias Modification (ABM)
Number of subjects: 88
Study 22281100 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 20133508 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous golimumab 50 mg
Number of subjects: 51
Study 20133508 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous golimumab 100 mg
Number of subjects: 51
Study 20133508 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous golimumab (both doses)
Number of subjects: 51
Study 19019650 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% HES
Number of subjects: 34
Study 19019650 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% HES
Number of subjects: 34
Study 19019650 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% albumin
Number of subjects: 34
Study 16435076 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisphosphonate therapy (10 mg alendronate or 5 mg risedronate) with calcium/vitamin D
Number of subjects: 56
Study 16435076 — intervention group
Group type: COMPARATOR
Intervention: Calcium/vitamin D treatment alone (control group)
Number of subjects: 56
Study 14984232 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (60 mg/day for 2 days, 40 mg/day for 2 days, and 20 mg/day for 2 days) for 6 days
Number of subjects: 150
Study 14984232 — intervention group
Group type: EXPERIMENTAL
Intervention: Naratriptan (2.5 mg twice a day) during the initial period
Number of subjects: 150
Study 14984232 — intervention group
Group type: COMPARATOR
Intervention: Nothing (no regular medications) during the initial period
Number of subjects: 150
Study 10858975 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 80 mg orally for 14 to 21 days
Number of subjects: 12
Study 10858975 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8976635 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive dynamic group exercises (full weight bearing and conditioning exercises on a stationary bicycle at 70-85% of age predicted maximum heart rate)
Number of subjects: 100
Study 8976635 — intervention group
Group type: COMPARATOR
Intervention: Range of motion (ROM) exercises and isometric exercises
Number of subjects: 100
Study 8976635 — intervention group
Group type: COMPARATOR
Intervention: Individual isometric and ROM exercises
Number of subjects: 100
Study 8976635 — intervention group
Group type: COMPARATOR
Intervention: Home instructions for isometric and ROM exercises
Number of subjects: 100
Study 1467613 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 200 micrograms bid
Number of subjects: 51
Study 1467613 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 6367406 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (120 mg)
Number of subjects: 12
Study 6367406 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (100 mg)
Number of subjects: 12
Study 6367406 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30053843 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence Rating Scale (ARS) based on exercise therapy adherence prediction model.
Number of subjects: 218
Study 27633621 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based intervention including teacher training, opportunities for PA, and health education.
Number of subjects: 548
Study 24912491 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (intravenous)
Number of subjects: 62
Study 24912491 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate with cocaine cue-video
Number of subjects: 62
Study 24912491 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate with neutral-video
Number of subjects: 62
Study 22962431 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 61
Study 22962431 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 61
Study 20434071 — intervention group
Group type: EXPERIMENTAL
Intervention: Dried prunes preload
Number of subjects: 45
Study 20434071 — intervention group
Group type: COMPARATOR
Intervention: Bread product preload
Number of subjects: 45
Study 18581129 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin injection
Number of subjects: 23
Study 15837450 — intervention group
Group type: EXPERIMENTAL
Intervention: Active intervention
Number of subjects: 0
Study 15837450 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15837450 — intervention group
Group type: EXPERIMENTAL
Intervention: Active intervention and Placebo
Number of subjects: 0
Study 12006904 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine
Number of subjects: 30
Study 12006904 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 30
Study 12006904 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 10541942 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP at 3 cmH(2)O
Number of subjects: 8
Study 10541942 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP at 6 cmH(2)O
Number of subjects: 8
Study 10541942 — intervention group
Group type: COMPARATOR
Intervention: PEEP at 0 cmH(2)O
Number of subjects: 8
Study 7802520 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid lowering treatment
Number of subjects: 36000
Study 7802520 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 36000
Study 2225715 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 250 mg
Number of subjects: 10
Study 2225715 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 7352849 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic community (more than seven weeks)
Number of subjects: 585
Study 7352849 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone maintenance
Number of subjects: 585
Study 7352849 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic community (less than seven weeks)
Number of subjects: 585
Study 7352849 — intervention group
Group type: COMPARATOR
Intervention: No treatment beyond short detoxification
Number of subjects: 585
Study 31479022 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic retinoscopy
Number of subjects: 95
Study 31479022 — intervention group
Group type: COMPARATOR
Intervention: Open-field autorefraction
Number of subjects: 95
Study 27670644 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifunctional diet (MFD)
Number of subjects: 44
Study 27670644 — intervention group
Group type: COMPARATOR
Intervention: Control diet devoid of the active components of MFD
Number of subjects: 44
Study 25967707 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-nitrogen and low-calorie parenteral nutrition combined with enteral nutrition (EN)
Number of subjects: 90
Study 25967707 — intervention group
Group type: COMPARATOR
Intervention: Total parenteral nutrition (TPN)
Number of subjects: 90
Study 24037015 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 25
Study 24037015 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Appliance
Number of subjects: 25
Study 24037015 — intervention group
Group type: COMPARATOR
Intervention: Physical Exercise
Number of subjects: 25
Study 22433704 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingavirin combined with an antibacterial agent
Number of subjects: 0
Study 22433704 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 0
Study 19673928 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged-release (PR) torasemide 5 mg
Number of subjects: 20
Study 19673928 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged-release (PR) torasemide 10 mg
Number of subjects: 20
Study 19673928 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release (IR) torasemide 5 mg
Number of subjects: 20
Study 19673928 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release (IR) torasemide 10 mg
Number of subjects: 20
Study 17061421 — intervention group
Group type: EXPERIMENTAL
Intervention: DBM putty composite (n = 10)
Number of subjects: 18
Study 17061421 — intervention group
Group type: COMPARATOR
Intervention: Iliac crest autograft (n = 8)
Number of subjects: 18
Study 15089807 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg kg(‐1) ephedrine sulphate
Number of subjects: 8
Study 15089807 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg kg(‐1) ephedrine sulphate
Number of subjects: 8
Study 15089807 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg kg(‐1) ephedrine sulphate
Number of subjects: 8
Study 15089807 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 11263615 — intervention group
Group type: EXPERIMENTAL
Intervention: Dofetilide
Number of subjects: 174
Study 11263615 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 174
Study 9626213 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 80 mg/m2 + Teniposide 100 mg/m2 (arm A)
Number of subjects: 332
Study 9626213 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 175 mg/m2 (arm B)
Number of subjects: 332
Study 9626213 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin + Teniposide (arm A)
Number of subjects: 332
Study 9626213 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel (arm B)
Number of subjects: 332
Study 7923659 — intervention group
Group type: EXPERIMENTAL
Intervention: c7E3 Fab (0.25 mg/kg bolus dose)
Number of subjects: 56
Study 7923659 — intervention group
Group type: EXPERIMENTAL
Intervention: c7E3 Fab (continuous infusion for up to 24 hours)
Number of subjects: 56